Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
BeOne Medicines extends its collaboration with quantitative systems pharmacology firm InSysBio, aiming to optimize clinical trial dosing and mitigate cytokine release syndrome risks across its broad portfolio of 15 novel oncology assets.
BeOne Medicines (NasdaqGS: ONC) has significantly expanded its strategic partnership with systems biology firm InSysBio. The deepened collaboration aims to leverage advanced mechanistic modeling to de-risk clinical trial design, with a particular focus on optimizing dosing and preempting safety challenges like cytokine release syndrome in oncology studies.
BeOne Medicines (ONC) presents a complex picture for investors, with recent short-term volatility contrasting sharply with strong long-term returns. As the stock trades around $340, analysts debate whether its current price fully reflects the ambitious growth narrative in its oncology pipeline.
Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.
The FDA clearance of Spectrum Dynamics' Veritas.AI platform marks a significant step forward for nuclear imaging, promising to cut scan times in half and enhance image clarity for critical applications like cancer theranostics.
As markets navigate a new year, analysts are eyeing potential outperformers. Amazon, BeOne Medicines, and Enterprise Products Partners emerge as compelling picks, each backed by distinct catalysts from AI to biotech breakthroughs.
Eli Lilly commits $85 million upfront and over $1.8 billion in potential milestones to partner with Repertoire Immune Medicines, aiming to develop a new class of 'tolerizing' therapies that reset the immune system without broad suppression.
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
KTM's preliminary 2025 financial results reveal a steep decline in revenue and sales, casting doubt on the efficacy of recent restructuring efforts and raising questions about the brand's near-term recovery trajectory.
The pharmaceutical giant's final major U.S. facility will rise in Pennsylvania's historic Lehigh Valley, aiming to produce its promising triple-hormone drug retatrutide and bolster domestic supply chains for blockbuster obesity treatments.
A sharp 16% weekly decline in enGene Holdings' share price puts significant pressure on its largest shareholder group—private equity firms controlling nearly half the company—raising questions about strategy and future direction amid broader market volatility.
While stocks priced between $10 and $50 can appear to offer an attractive balance of accessibility and maturity, their low price tags can sometimes mask underlying vulnerabilities. We examine three such companies where caution may be prudent.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility dedicated to next-generation weight-loss drugs, signaling a long-term strategic commitment to the obesity market amid intense competition.
Erasca (ERAS) gains significant analyst momentum as Mizuho initiates coverage with an 'Outperform' rating and a $16 price target, citing confidence in its 2026 proof-of-concept milestones for RAS-targeted cancer therapies.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
The vital Rafah border crossing between Gaza and Egypt reopened Monday for strictly limited passenger traffic, marking a tentative step in the implementation of the Israel-Hamas ceasefire. The move, described as largely symbolic for now, offers a glimmer of hope for thousands of Palestinians seeking medical care or a return home.
Harmony Biosciences CFO Sandip Kapadia has liquidated his entire direct stake in the company, a move that contrasts sharply with the firm's robust financial performance and bullish $1 billion revenue target for its flagship drug WAKIX by 2026. While the sales were pre-planned, the timing fuels debate on insider confidence versus corporate optimism.
IDEAYA Biosciences shares have retreated from recent highs, presenting investors with a dilemma. While long-term performance remains strong, its premium valuation and significant net losses raise questions about whether the current price already reflects its promising pipeline.
